Document is current
Any future updates will be listed below
-
Authors
Stroik, Susanna
Carvajal-Garcia, Juan https://orcid.org/0000-0001-7257-3674
Gupta, Dipika https://orcid.org/0000-0002-6512-5256
Edwards, Alyssa https://orcid.org/0000-0002-1968-7186
Luthman, Adam
Wyatt, David W.
Dannenberg, Rachel L.
Feng, Wanjuan
Kunkel, Thomas A. https://orcid.org/0000-0002-9900-1788
Gupta, Gaorav P. https://orcid.org/0000-0001-9177-552X
Hedglin, Mark https://orcid.org/0000-0003-2599-1691
Wood, Richard https://orcid.org/0000-0002-9495-6892
Doublié, Sylvie
Rothenberg, Eli https://orcid.org/0000-0002-1382-1380
Ramsden, Dale A. https://orcid.org/0000-0003-1575-4748
- License Information
-
More Information
Article History
Received: 12 September 2022
Accepted: 6 October 2023
First Online: 15 November 2023
Competing interests
: D.A.R. has a materials transfer agreement with Artios Pharma and used an Artios Polθ inhibitor for research purposes in this work with no financial compensation. R.D.W. owns shares in Repare Therapeutics, Inc., which also has a Polθ inhibitor.
